Gemphire Therapeutics Overview

  • Founded
  • 2008
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Gemphire Therapeutics General Information

Description

Developer of novel therapies designed to treat life threatening cardiovascular or metabolic and orphan diseases. The company is engaged in developing and commercializing therapies for patients with cardiometablic disorders including dyslipidemia and nash.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 17199 North Laurel Park Drive
  • Suite 401
  • Livonia, MI 48152
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gemphire Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 30-Dec-2019 00000 Completed Generating Revenue
6. Secondary Transaction - Private 00000 Completed Generating Revenue
5. PIPE 04-Sep-2017 0000 00000 Completed Generating Revenue
4. PIPE 10-Mar-2017 000.00 000.00 Completed Generating Revenue
3. IPO 04-Aug-2016 0000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 09-Mar-2016 $10.6M $10.6M 0000 Completed Generating Revenue
1. Angel (individual) Completed Generating Revenue
To view Gemphire Therapeutics’s complete valuation and funding history, request access »

Gemphire Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Gemphire Therapeutics’s complete cap table history, request access »

Gemphire Therapeutics Patents

Gemphire Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3867222-A1 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor Pending 18-Oct-2018 0000000000
US-20200253877-A1 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor Pending 18-Oct-2018 0000000000
US-20190008779-A1 Gemcabene compositions and methods of use thereof Abandoned 11-May-2017 0000000000
US-20200148617-A1 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor Pending 18-Apr-2017 000000000
EP-3612171-A1 Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor Pending 18-Apr-2017 C07C62/08

Gemphire Therapeutics Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amherst Fund Venture Capital Minority 000 0000 000000 0
Biobrit Venture Capital Minority 000 0000 000000 0
Biosciences Research and Commercialization Center Venture Capital Minority 000 0000 000000 0
BlueWater Angels Angel Group Minority 000 0000 000000 0
Capital Midwest Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Gemphire Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 30-Jan-2020 0000000 000000 Biotechnology
To view Gemphire Therapeutics’s complete acquisitions history, request access »